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Abstract
Background: Diabetic kidney disease (DKD) is one of the most common microvascular complications of diabetes
mellitus and the main cause of end-stage renal disease. Present medications for DKD are not entirely satisfactory.
Preliminary studies indicate that the Chinese herbal formula Tangshen Formula (TSF) appears to decrease the proteinuria
and improve the estimated glomerular filtration rate (eGFR) in DKD patients.
Methods/design: This trial is a five-center, randomized, double-blind, placebo-controlled study. DKD patients with a
24-h urinary protein (24 h UP) level between 0.5 and 3.5 g and serum creatinine < 265 μmol/L (3 mg/dl) will be included.
A sample size of 144 participants will be randomly distributed into the treatment group (TSF plus irbesartan) and
the control group (placebo plus irbesartan) at a ratio of 1:1. The study duration will be 50 weeks, comprising a
2-week run-in period, 24 weeks of intervention, and 24 weeks of follow-up. The primary endpoint will be the 24 h
UP. Secondary endpoints will be an evaluation of renal function, management of blood lipids, improvement in
traditional Chinese medicine symptoms, and safety assessments. Adverse events will also be evaluated.
Discussion: This study will provide evidence for the effectiveness and safety of TSF compared to placebo in treating
DKD patients with macroalbuminuria.
Trial registration: Chinese Clinical Trials Registry, ChiCTR-TRC-13003566. Registered 9 August 2013.
Keywords: Chinese herbal medicine, Diabetic kidney disease, Macroalbuminuria, Randomized controlled trial,
Tangshen Formula
Background
Diabetic kidney disease (DKD) is a major microvascular
complication of both type 1 and type 2 diabetes mellitus
(DM) [1]. However, in type 1 diabetics, DKD typically does
not present until the second decade after diagnosis of dia-
betes, whereas in some type 2 diabetics, DKD is already
evident at the time of diagnosis of diabetes because of
other chronic instigators of kidney injury such as aging,
hypertension, and abnormal lipid levels [2, 3]. In China,
DKD is the second leading cause of end-stage renal disease
(ESRD) after glomerulonephropathy [4] and is a leading
cause of dialysis in developed countries such as Japan and
the USA [5, 6]. The economic burden of DKD is substan-
tial [7, 8]. Angiotensin-converting enzyme inhibitors
(ACEIs) and angiotensin receptor blockers (ARBs) have
been the agents of choice in slowing the progression of
DKD. However, as seemingly effective as they are, these
drugs have side effects such as rhinitis, persistent cough,
and angioedema, which cause patients to discontinue
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therapy in some cases [9, 10]. Thus, it is clear that an
unmet need exists for developing renoprotective therapies
that are not only effective but also well tolerated.
Recent studies appear to show that certain Chinese
herbs have renoprotective effects against chronic kidney
disease (CKD) [11] and DM [12]. Hence, to assess the effi-
cacy and safety of these herbs in DKD treatment, a well-
designed, randomized, controlled trial (RCT) is needed.
Traditional Chinese medicine (TCM) is a medical system
founded on syndrome pattern differentiation. Clarifying
the main TCM syndrome type of DKD is essential for its
treatment. We employed the Delphi method to investigate
the most common signs and symptoms of DKD as pro-
pounded by TCM nephrology experts. From three rounds
of questionnaires, we concluded that deficiency of both qi
and yin with blood stasis is the main TCM syndrome type
of DKD [13]. This result was in accordance with findings
of other studies [14, 15] and was verified in our subsequent
cross-sectional study of 350 DKD patients [16]. Based on
this main syndrome type and empirical evidence from
Chinese medicine practitioners, the herbs in Tangshen For-
mula (TSF) were chosen to treat DKD. The TCM function
of the herbs in TSF is to replenish qi and yin and to pro-
mote blood circulation. Ensuing studies suggested that TSF
treatment could decrease the urinary albumin excretion
rate (UAER) and reduce glomerulosclerotic and interstitial
fibrosis indices in both Otsuka Long-Evans Tokushima
fatty (OLETF) spontaneously diabetic rats [17] and strepto-
zotocin combined with uninephrectomy-induced type 1
diabetic rats [18]. Further research indicated that in DKD
rats, the therapeutic effects of TSF might at least be par-
tially due to its anti-inflammatory action of downregulating
tumor necrosis factor α and upregulating pro-inflammatory
cytokine interleukin-10 [19], as well as its antifibrotic action
of inhibiting expression of transforming growth factor beta
1 (TGF-β1) in renal tissue, enhancing the expression of
matrix metallopeptidase 9 (MMP-9), and reducing the ex-
pression of collagen type IV [18]. Another study of ours
also found that TSF appears to exert a renal protective ef-
fect by improving lipid metabolism [20]. Our preliminary
RCT indicated that TSF treatment might improve eGFR
and decrease proteinuria, especially in patients with macro-
albuminuria [21].
The current study is designed to validate whether or
not TSF is safe and efficacious in the treatment of DKD
patients with macroalbuminuria.
Methods/design
Ethics, consent, and permissions
The protocol (version identifier: TSF-3.0 (20130512))
has been approved by the ethics committee of the
China-Japan Friendship Hospital (Approval No. 2013–46)
and is registered with the Chinese Clinical Trial Registry
(http://www.chictr.org.cn) under registration number
ChiCTR-TRC-13003566. The study will be conducted in
accordance with the principles of good clinical practice, i.e.,
the Declaration of Helsinki (2004 version). The trial will be
reported according to the Standard Protocol Items: Recom-
mendations for Intervention Trials (SPIRIT) (see Add-
itional file 1). All patients will be informed about the
purpose of the trial, the risks, and the benefits, and in-
formed consent (see Additional file 2) will be obtained
from all participants prior to entry into the trial. All
visits will be documented in a case report form (CRF).
Study design and setting
This trial will be a randomized, placebo-controlled, multi-
center trial with two parallel groups. Investigators, the stat-
istician, and participants will be blinded. The trial flow is
illustrated in Fig. 1. Five hospitals in China will participate
in the study: the China-Japan Friendship Hospital, Beijing;
the First Teaching Hospital of Tianjin University of Trad-
itional Chinese Medicine, Tianjin; the Hangzhou Hospital
of Traditional Chinese Medicine Affiliated to Zhejiang
University of Chinese Medicine, Hangzhou; the Shaanxi
Provincial Hospital of Traditional Chinese Medicine, Xi’an;
and the Longhua Hospital Affiliated to Shanghai University
of Traditional Chinese Medicine, Shanghai.
Eligibility criteria
Diagnostic criteria
The diagnosis of type 2 diabetes will be based on the
American Diabetes Association (ADA) criteria [22],
Fig. 1 Flow diagram of progress through the study
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and DKD will be defined by the National Kidney
Foundation Kidney Disease Outcomes Quality Initia-
tive (NKF K-DOQI) guidelines [23].
TCM syndrome pattern differentiation
The Chinese syndrome pattern differentiation type of
deficiency of both qi and yin with blood stasis will be
based on guidelines delineated in Clinical Research of
New Investigational Drugs in Traditional Chinese Medi-
cine [24]. The diagnostic standards are as follows:
1. Primary signs and symptoms include fatigue,
listlessness, weakness, and soreness of the low back
and knees; heat sensation in the palms and soles;
and dry mouth and throat.
2. Secondary signs and symptoms include catching
cold easily, pale complexion, irritability, numbness,
edema, frequent urination at night, constipation, and
hematuria.
Participants will be diagnosed with deficiency of both
qi and yin with blood stasis syndrome if they have two
or more of the primary signs/symptoms and at least two
of the secondary signs/symptoms. Investigators at each
center will administer a symptom assessment survey to
every participant (Table 1). This will ensure standardized
scoring across centers.
After being screened for inclusion and exclusion criteria
(Table 2), eligible patients will be entered into the trial.
Interventions
Eligible participants will be randomized to either the
TSF or placebo group, receiving oral administration of
either TSF or placebo (12 g per packet) twice daily for
24 weeks.
TSF consists of seven natural herbs: astragalus root
(Astragalus membranaceus (Fisch.) Bge.), rehmannia
root (Rehmannia glutinosa (Gaertn.) Libosch.), notogin-
seng root (Panax notoginseng (Burk.) F. H. Chen), winged
burning bush twig (Euonymus alatus (Thunb.) Sieb.), Asi-
atic cornelian cherry fruit (Cornus officinalis Sieb. Et Zucc.),
rhubarb root and rhizome (Rheum palmatum L.), and bit-
ter orange (Citrus aurantium L.).
Both TSF (Lot No. 1206388) and the placebo were
manufactured by the Jiangyin Tianjiang Pharmaceutical
Company (Jiangyin, China). The manufacturing process
was quality controlled for physical characteristics, pur-
ity, microbial content, and weight consistency of the
packets. Certificates of quality for the manufacturing of
TSF and placebo have been provided by the manufac-
turer (Additional file 3). The main components in TSF
were validated and quantified by thin-layer chromatog-
raphy and high-performance liquid chromatography.
Table 1 Traditional Chinese medicine (TCM) symptom
assessment survey
Fatigue □ 0: None
□ 2: Cannot sustain heavy work
□ 4: Can manage mild intensity work
□ 6: Can only do daily activities
Weakness and soreness of the
low back and knees
□ 0: None
□ 2: Occasional
□ 4: Need to alter body position for
relief
□ 6: Persistent pain, need to take pain
medication




□ 4: Desire to expose extremities
□ 6: Desire to hold something cold
Dry mouth and throat □ 0: None
□ 2: Mild
□ 4: Decreased saliva production
□ 6: Severe thirst with constant need
to drink fluids
Qi deficiency and listlessness □ 0: None
□ 2: Shortness of breath after mild
activity
□ 4: Shortness of breath after moderate
activity
□ 6: Unable to talk or catch breath even
without activity
Catch cold easily □ 0: No colds
□ 1: At least 6 times per year
□ 2: At least 10 times per year
□ 3: 12 or more times per year
Pale complexion □ 0: None
□ 1: Mild
□ 2: Moderate
□ 3: Pale or dark yellow complexion
Irritability □ 0: None
□ 1: Occasional
□ 2: Easily irritated, but able to gain
self-control
□ 3: Severe agitation, unable to gain
self-control
Numbness □ 0: None
□ 1: Hands and feet
□ 2: Limbs
□ 3: Entire body
Edema □ 0: None
□ 1: Palpebral edema in the morning
□ 2: Palpebral and lower limb edema





□ 1: 2 times
□ 2: 3 to 4 times
□ 3: 5 times or more
Constipation □ 0: None
□ 1: Hard stools and straining
□ 2: Hard stools with a 2 to 3 days
between bowel movements
□ 3: Hard stools with 3 or more days
between bowel movements
Hematuria □ 0: None
□ 1: Yes
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Concomitant treatments
Based on the 2013 American Diabetes Association (ADA)
practice guidelines, all participants will receive standard
treatments as follows:
1. Irbesartan: Irbesartan will be selected as the basic
treatment to lower proteinuria and protect renal
function. All participants will take irbesartan orally
at a dosage of 300 mg daily.
2. Antihypertensive drugs: Participants with hypertension
will receive antihypertensive drugs to maintain a blood
pressure of ≤ 130/80 mmHg. Non-dihydropyridine
calcium channel blockers or alternatively, beta
blockers, will be the recommended drugs. If the
blood pressure cannot be maintained at 130/80 mmHg
by the combination of these two drugs, diuretics will
be added.
3. Blood glucose control therapy: The A1C of all
participants will be controlled to ≤ 8.0 % throughout
the trial. Metformin will be used for participants
with eGFR above 60 ml/min. For participants with
eGFR below 60 ml/min, oral repaglinide will be the
alternative. For participants whose A1C cannot be
controlled with oral agents, insulin will be used.
4. Antilipemic agents: Participants with hyperlipidemia
will receive atorvastatin.
Participants will also be instructed to follow a low-
sodium diabetes diet, including a reasonable intake of
calories, protein, carbohydrates, and fat. They will also
be asked to exercise regularly. Administration of other
medications will be at the discretion of the attending
physician investigator and would not interfere with out-
come assessments. Investigators will be instructed to
record in the CRF the details of any additional/trans-
formational drug or therapy, such as the name, dosage,
and duration of administration.
Prohibited concomitant medications
During the trial period, use of any other drugs that could
affect urinary protein or renal function will be prohibited.
This includes TCMs that function to replenish qi and yin
or promote blood circulation. Other prohibited agents
include vitamin D, spironolactone, pentoxifylline, rhubarb
sodium bicarbonate tablets, aminoglycoside antibiotics,
nonsteroidal anti-inflammatory drugs, and antiviral drugs.
If participants use any of the above-mentioned drugs, they
will be withdrawn from the study.
Study visits and assessment
Study duration will be 50 weeks, comprised of a 2-week
run-in period, 24 weeks of intervention, and 24 weeks of
follow-up. After treatment commences, visits will occur
every 4 weeks during the intervention period. During the
follow-up period, participants will be asked to visit at 28,
36, and 48 weeks. An overview of specific measurements
and time points of data collection can be found in Table 3.
Outcome measurements
Primary endpoint
The primary endpoint is 24 h UP. The change in 24 h UP
from baseline to 24 weeks will be the analysis metric for
the difference between the two groups. At baseline and
treatment endpoint (24 weeks), the average values of two
different samples collected within 1 week will be used to
minimize variation between the different urine samples.
Secondary endpoints
Secondary endpoints will be as follows:
1. Change in serum creatinine (SCr) and eGFR (2009
CKD-EPI creatinine equation [25]) from baseline to
24 weeks
2. Change in blood lipid profile of total cholesterol
(TC), triglyceride (TG), high-density lipoprotein
cholesterol (HDL-C), and low-density lipoprotein
cholesterol (LDL-C) from baseline to 24 weeks
3. Improvement in TCM symptoms (evaluation by
TCM symptom score scale) from baseline to
24 weeks
4. Safety assessment: Results of routine blood and urine
tests, electrocardiogram (ECG), alanine
aminotransferase (ALT), aspartate aminotransferase
Table 2 Eligibility criteria
Inclusion criteria Exclusion criteria
• DKD diagnostic criteria:
a) Type 2 diabetes
b) Diabetic retinopathy
c) 24-h urinary protein (24 h UP)
0.5–3.5 g
• Serum creatinine <265 μmol/L
(3 mg/dl)
• Controlled hypertension (blood
pressure ≤ 130/80 mmHg)
• A1C ≤ 8.0
• Chinese syndrome differentiation
of qi and yin deficiency with
blood stasis
• Taking irbesartan (300 mg daily)
continuously in the past 2 weeks
• Between 18 and 70 years of age
• Sign informed consent
• Blood pressure < 90/60 mmHg
• Serum potassium > 5.5 mmol/L
or < 3.5 mmol/L
• Doubling of serum creatinine in
the past 6 months
• Renal artery stenosis
• Severe diabetes complications or
serious macrovascular events
within 6 months (e.g., cerebral
hemorrhage, massive cerebral
infarction, or acute myocardial
infarction)
• Recent infection in the past
4 weeks
• Other primary or secondary renal




• Severe mental disorder
• Pregnant or lactating women or
women with the intention of
becoming pregnant or women
who are not using appropriate
contraceptive methods
• Allergic to components of agents
used in the study
• Participation in other clinical trials
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(AST), alkaline phosphatase (ALP), gamma-glutamyl
transpeptidase (GGT), and serum total bilirubin
(TBIL) tests will comprise the comprehensive
safety assessment. The safety endpoints will
include the incidence and severity of drug-
induced liver injury (DILI) and bone marrow
suppression (BMS), as well as the incidence of
QTc prolongation, as measured by ECG. DILI is
defined by criteria established by the Inter-
national Serious Adverse Events Consortium [26].
The causality relationship between DILI and the
intervention drug will be assessed with the
Roussel Uclaf Causality Assessment Method
(RUCAM) [27]. Severity is scored on a range
from 1 (mild) to 5 (fatal) [28]. The diagnosis and
severity of bone marrow suppression will be
assessed by criteria established by the World
Health Organization Collaborating Centre for
International Drug Monitoring [29]: grade I:
white blood cell (3.0–3.9) × 109/l, hemoglobin
95–100 g/l, platelet (75–99) × 109/l; grade II:
white blood cell (2.0–2.9) × 109/l, hemoglobin
80–94 g/l, platelet (50–74) × 109/l; grade III:
white blood cell (1.0–1.9) × 109/l, hemoglobin
65–79 g/l, platelet (25–49) × 109/l; grade IV:
white blood cell (0–1.0) × 109/l, hemoglobin
< 65 g/l, platelet < 25 × 109/l. QTc longer than
0.44 second is regarded as prolongation.
Additional measurements
Tests for A1C and serum C-reactive protein (CRP) will
be carried out at study visits 4, 8, 16, and 24 weeks.
Adverse events
Adverse events (AEs) such as signs and symptoms and
other ailments will be documented at every study visit.
Each AE will be classified as a mild, moderate, or severe
AE, and its correlation with the intervention drugs will
be assessed. Severe AEs will be reported to the principal
investigator and the ethics committee within 24 h. All
the adverse events will be recorded, monitored, and
treated until properly resolved.
Quality control of laboratory specimens
To eliminate potential discrepancies resulting from the
handling of laboratory specimens by different labs,
which may compromise data quality, samples collected
at patient visits from all five participating medical cen-
ters will be cold-chain transported to a single laboratory
(KingMed Diagnostics, Guangzhou) for processing. Data
from KingMed will be quality controlled and securely
transmitted in batches via e-mail back to participating
sites and the principal investigators.
Blood and urine samples will be collected on site by a
trained phlebotomist using standard techniques. The
serum of each blood sample will be separated by centrifu-
gation (3000 g, 15 minutes, 4 °C). Samples will be analyzed
Table 3 Schedule of enrollment, allocation, visits, and assessments
Study Period
Enrollment Allocation Intervention Follow-up
Time point (weeks) −2 0 4 8 12 16 20 24 28 36 48
Eligibility screen √
Written informed consent √
Medical history √
Physical examination √ √ √ √ √ √ √
Routine blood and urine √ √ √ √
Electrocardiogram √ √ √ √
ALT, AST, ALP, GGT, TBIL √ √ √ √
24 h urinary protein √ √ √ √ √ √ √ √
Serum Cr, eGFR √ √ √ √ √ √ √ √
TC, TG, LDL-C, HDL-C √ √ √ √ √
A1C, CRP √ √ √ √
Evaluation of TCM syndrome √ √ √ √ √ √ √ √ √ √
Drug distribution √ √ √ √ √ √
Retrieval of unused drugs √ √ √ √ √ √
Adverse events √ √ √ √ √ √ √ √ √
Abbreviations: A1C hemoglobin A1C, ALP alkaline phosphatase, ALT alanine transaminase, AST aspartate aminotransferase, eGFR estimated glomerular filtration rate,
GGT gamma-glutamyl transpeptidase, LDL-C low-density lipoprotein cholesterol, serum Cr serum creatinine, TBIL total bilirubin, TC total cholesterol, TCM traditional
Chinese medicine, TG triglycerides, HDL-C high-density lipoprotein cholesterol
√ = Action items
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by an automated biochemistry analyzer (Roche Modular
P800, Roche Diagnostics, Lewes, UK) using validated
commercial kits. The 24 h UP and CRP will be assayed by
immunoturbidimetry. Serum levels of sodium, potassium,
and chlorine will be detected by ion-selective electrode
methodology. Bilirubin will be determined by the diazo
method. ALT, AST, ALP, and GGT will be measured by
the velocity method. A direct method will be used for the
quantitative determination of LDL-C and HDL-C. An en-
zymatic method will be used to assay SCr and TG. Choles-
terol will be measured by the cholesterol oxidase method.
Sample size estimation
The sample size was estimated based on results from
our preliminary trial. These results found that after a 24-
week treatment period, the mean reduction in 24 h UP
in the placebo group was 0.40 ± 0.91 g; the mean reduc-
tion in 24 h UP in the TSF group was −0.31 ± 0.95 g.
The least-squares mean of the difference value between
the relative changes from baseline (TSF group-placebo
group) was −0.54. The proportion of the cases between
the TSF group and placebo group will be 1:1. With 80 %
power to detect and a two-sided level of significance of
0.05, the sample size was estimated to be 54 in each
group. In order to increase the accuracy of the data ob-
tained, this number was increased to 60. Assuming a
dropout rate of 20 %, the final sample size was estimated
to be 144.
Randomization and concealment
Randomization will be carried out by an independent
clinical research organization (CRO) from the Beijing
Qihuang Drug Clinical Research Center. The CRO will
use a computerized random number generator to pro-
duce the randomization schedule employing permuted
blocks of random sizes. Participants will be randomly
assigned to either the control or the TSF group at a 1:1
allocation. The drug administrator at each participating
medical center will enroll patients sequentially based on
consultation order. The blocks should provide compar-
able numbers of participants in both groups at any time
in the course of the trial. To ensure concealment, the
block sizes will not be disclosed. The randomization list
will be retained by the Beijing Qihuang Drug Clinical
Research Center for the duration of the study.
Blinding
This study will implement a double-blind design in
which participants and investigators will be blinded to
treatment allocation. The statistician will not be involved
in randomization and will analyze data without having
access to information about allocation. Treatment allo-
cation will be disclosed after the conclusion of the trial
except in cases of emergency, such as severe AEs. Both
TSF and placebo are manufactured as fine brown granules
and packaged in packets identical in appearance. When
dissolved in warm water, the taste, smell, and appearance
of the TSF and placebo are identical. Investigators and
participants will be unaware of the drug allocation.
Statistical analysis
This trial will use three analysis sets: the intention-to-treat
set, which will regard all participants as randomized re-
gardless of whether or not they received the randomized
treatment; the per protocol analysis set, which will be
restricted to participants who complete the 24-week treat-
ment and/or have the primary endpoint measurement re-
cords of at least three time points during the study; and
the safety analysis set, which will include randomized
participants who have made at least one visit. Multiple im-
putation analysis will be performed to account for the
effect of missing data. Partially missing data will be carried
forward with the principle of the last observation carried
forward (LOCF). A P value less than 0.05 will be consid-
ered significant. SAS 9.2 software (SAS Institute, Cary,
NC, USA) will be used for analysis.
Continuous variables will be expressed as the mean
(SD), and categorical variables, as numbers and percent-
ages. To compare baseline data between the two groups,
independent t tests (or the Mann–Whitney U test) will
be used to analyze continuous data, and chi-square or
Fisher exact test will be used for categorical data. Out-
come analysis will be performed using t test for normally
distributed data and rank sum test for non-normal dis-
tribution data. Considering that the baseline 24 h UP
and/or A1C are essential for the progression of urinary
protein, analysis of covariance (ANCOVA) using 24 h
UP and/or A1C as covariates will be performed to
analyze the 24 h UP reduction at 24 weeks. To investi-
gate the effects of treatment and time course, repeated
measures analysis of variance (ANOVA) will be applied
to determine changes in the 24 h UP and eGFR at each
visit. For safety endpoints, incidences of DILI and BMS
will be analyzed by Kruskal-Wallis test, and the inci-
dence of QTc will be evaluated by a chi-square test. For
AE evaluation, all AEs will be reported including its
grade, time of occurrence, duration, treatment, progno-
sis, and correlation with the intervention drugs. The chi-
square test or Fisher exact test will be used to compare
the incidence of AEs between the two groups.
Data collection and management
Investigators at all sites will be trained uniformly in
standard operating procedures (SOPs) for trial execu-
tion, interrogation of TCM symptoms, laboratory speci-
men collection, and handling. The CRO will pay regular
visits to each site to confirm protocol adherence and the
quality of data collection, and resolve any issues the site
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has. To ensure the accuracy of data entry, non-numeric
data will be coded for ease of data storage; analysis and
referential data rules, valid values, range checks, and
consistency checks against data already stored in the
database will also be supported. After verification of the
content of the written CRFs, data will be input into the
database independently by two full-time research staff.
All documents will be stored safely under confidential
conditions and archived for 5 years.
Participant retention and withdrawal
To prevent missing data and to avoid associated complex-
ities in the study analysis, once a patient is randomized,
investigators will make reasonable efforts to follow the
patient for the entire study period. Efforts will include the
following:
1. Reimbursement of participants for public
transportation costs
2. Scheduling and reminding participants of their
return visits
3. Reimbursing participants in the placebo group at the
conclusion of the trial
Participants may withdraw from the study for any reason
at any time, and the reason will be recorded in the CRF. In-
vestigators can also withdraw participants from the study
to protect their safety. Reasons that can prompt withdrawal
include the following:
1. Rapidly increasing serum creatinine of more than
50 % of baseline after 2 to 4 weeks of treatment
2. Decreasing eGFR of more than 50 % of the baseline
after 2 to 4 weeks of treatment
3. Development of severe complications and/or
deterioration of an existing health condition
Discussion
TCM is a millennia-old medical practice based on syn-
drome pattern differentiation and is applied to treat a
variety of diseases in China. In modern times, TCM is
prescribed by most doctors in China as a basic or com-
plementary therapy for kidney disease. TSF is prescribed
to treat DKD patients with the most common syndrome
pattern of deficiency in qi and yin. Laboratory studies
and clinical observations have shown that TSF appears
to be efficacious [17, 18]. We are therefore undertaking
this trial to validate its efficacy and safety for the treat-
ment of DKD.
The quality of the RCTs conducted on TCM therapies
is generally poor [30]. Issues include poor study design
and methodology, and a lack of training of the investiga-
tors and staff. To ensure the quality of this study and
reliability of our conclusions, the experimental design
and study implementation have been carried out to date
under strict quality control. Statisticians are involved in
the study design to conduct sample size estimation, ran-
dom allocation sequence generation, randomization con-
cealment, and blinding. The Consolidated Standards of
Reporting Trials (CONSORT) Extension for Herbal In-
terventions [31] has been used to monitor other points
of the study design. A training session for each center
has been held to explain the study protocol, explain how
the TCM syndrome pattern differentiation should be
performed, and clarify the SOPs. An independent labora-
tory will process the biochemical measurements. Add-
itionally, the trial progress and quality will be monitored
by a trained CRO.
The findings of this study may provide an alternative
treatment option for DKD patients with macroalbumi-
nuria. It will also provide evidence and a scientific ra-
tionale for the use of TSF to treat the macroalbuminuria
stage of DKD.
Trial status
The trial is currently ongoing and 123 patients have been
recruited.
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